Soleus Capital Management’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-287,246
| Closed | -$1.3M | – | 97 |
|
|
2025
Q3 | $1.3M | Hold |
287,246
| – | – | 0.07% | 78 |
|
|
2025
Q2 | $618K | Hold |
287,246
| – | – | 0.04% | 90 |
|
|
2025
Q1 | $1.26M | Hold |
287,246
| – | – | 0.09% | 70 |
|
|
2024
Q4 | $1.34M | Hold |
287,246
| – | – | 0.08% | 72 |
|
|
2024
Q3 | $2.02M | Buy |
287,246
+140,000
| +95% | +$1.02M | 0.16% | 78 |
|
|
2024
Q2 | $1.01M | Buy |
+147,246
| New | +$1.37M | 0.09% | 84 |
|
|
2024
Q1 | – | Sell |
-42,500
| Closed | -$320K | – | 93 |
|
|
2023
Q4 | $320K | Buy |
+42,500
| New | +$388K | 0.04% | 70 |
|
|
2023
Q3 | – | Sell |
-32,000
| Closed | -$509K | – | 93 |
|
|
2023
Q2 | $509K | Buy |
+32,000
| New | +$336K | 0.06% | 95 |
|
|
2022
Q4 | – | Sell |
-558,779
| Closed | -$5.31M | – | 73 |
|
|
2022
Q3 | $5.31M | Buy |
+558,779
| New | +$7.34M | 0.72% | 41 |
|
|
2021
Q2 | – | Sell |
-9,999
| Closed | -$986K | – | 66 |
|
|
2021
Q1 | $986K | Sell |
9,999
-3,600
| -26% | -$432K | 0.18% | 66 |
|
|
2020
Q4 | $1.47M | Sell |
13,599
-22,836
| -63% | -$2.83M | 0.19% | 46 |
|
|
2020
Q3 | $3.75M | Buy |
36,435
+14,563
| +67% | +$2.18M | 1.99% | 21 |
|
|
2020
Q2 | $4.57M | Sell |
21,872
-9,518
| -30% | -$1.69M | 2.6% | 12 |
|
|
2020
Q1 | $3.07M | Sell |
31,390
-2,890
| -8% | -$337K | 3.57% | 10 |
|
|
2019
Q4 | $3.95M | Buy |
+34,280
| New | +$3.02M | 3.81% | 6 |
|
Soleus Capital Management's ADVM Position: Q4 2025 in Review
Soleus Capital Management sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 287,246 shares — an estimated $1.3M sold.
Soleus Capital Management first reported a position in ADVM in Q4 2019 and held it in 15 quarters. The position peaked at $5.31M in Q3 2022. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- Soleus Capital Management reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- Soleus Capital Management sold 287,246 Adverum Biotechnologies shares in Q4 2025, an estimated $1.3M.
- Soleus Capital Management first reported a position in Adverum Biotechnologies in Q4 2019 and held it in 15 quarters.
- Soleus Capital Management's Adverum Biotechnologies position peaked at $5.31M in Q3 2022.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on Soleus Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.